Swiss National Bank
ADMS

Swiss National Bank’s Adamas Pharmaceuticals ADMS Stock Holding History

Swiss National Bank’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-39,900
Closed -$284K – 2584
2019
Q1 		$284K Buy
39,900
+2,500
+7% +$22.5K ﹤0.01% 2466
2018
Q4 		$319K Hold
37,400
– – ﹤0.01% 2460
2018
Q3 		$749K Hold
37,400
– – ﹤0.01% 2287
2018
Q2 		$966K Buy
+37,400
New +$1.04M ﹤0.01% 2177

Other funds holding ADMS

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Swiss National Bank's ADMS Position: Q2 2019 in Review

Swiss National Bank sold out of Adamas Pharmaceuticals (ADMS) in Q2 2019, closing a stake of 39,900 shares — an estimated $284K sold.

Swiss National Bank first reported a position in ADMS in Q2 2018 and held it in 4 quarters. The position peaked at $966K in Q2 2018. 78 funds tracked by Wall St. Rank hold ADMS as of Q2 2019.

  • Swiss National Bank reported no remaining Adamas Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Swiss National Bank sold 39,900 Adamas Pharmaceuticals shares in Q2 2019, an estimated $284K.
  • Swiss National Bank first reported a position in Adamas Pharmaceuticals in Q2 2018 and held it in 4 quarters.
  • Swiss National Bank's Adamas Pharmaceuticals position peaked at $966K in Q2 2018.
  • 78 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q2 2019.

Based on Swiss National Bank's 13F filing for Q2 2019, filed 2 Aug 2019.